Ann: Security Class Reinstatement to Quotation- OPTOB, page-58

There are still quite a few milestones to hopefully tick off. 1, The results of the Eyelea Trial 2. The results of the Lucentis trial 3. The FDA submission 4 Approval from the FDA 5. The results of the safety part of the trials. If the trials are successful then we will almost certainly see a significant appreciation in the market cap and conversion of all of the August 2025 options which will simultaneously dilute the shares currently on issue and give the company more working capital. Likewise the end of the safety evaluation should see a mass conversion of the June 2026 options.